CORCEPT THERAPEUTICS INC Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost
CORCEPT THERAPEUTICS INC (CORT) had Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost of $27.84 million as of 2025-12-31, per its 10-K filed 2026-02-24.
Financial Statements › Notes › Income Taxes › Components of Deferred Tax Assets and Liabilities › Components of Deferred Tax Assets › Deferred Tax Assets, Net › Deferred Tax Assets, Net of Valuation Allowance › Deferred Tax Assets, Gross › Deferred Tax Assets, Tax Deferred Expense
us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost · last filed 2026-02-24
- 2025-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $27.84M.
- 2024-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $25.30M.
- 2023-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $21.68M.
- 2022-12-31: Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost $17.96M.
| Period end | Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost |
|---|---|
| 2025-12-31 | $27.84M 10-K · filed 2026-02-24 |
| 2024-12-31 | $25.30M 10-K · filed 2026-02-24 |
| 2023-12-31 | $21.68M 10-K · filed 2025-02-26 |
| 2022-12-31 | $17.96M 10-K · filed 2024-02-15 |
| 2021-12-31 | $17.83M 10-K · filed 2023-02-28 |
| 2020-12-31 | $14.04M 10-K · filed 2022-02-15 |
| 2019-12-31 | $12.03M 10-K · filed 2021-02-23 |
| 2018-12-31 | $9.12M 10-K · filed 2020-02-24 |
| 2017-12-31 | $5.60M 10-K · filed 2019-02-26 |
| 2016-12-31 | $6.51M 10-K · filed 2018-02-28 |
| 2015-12-31 | $6.25M 10-K · filed 2017-03-06 |
| 2014-12-31 | $6.41M 10-K · filed 2016-03-10 |
| 2013-12-31 | $5.40M 10-K · filed 2015-03-13 |
| 2012-12-31 | $4.32M 10-K · filed 2014-03-14 |
| 2011-12-31 | $3.06M 10-K · filed 2013-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |